Pulmicort (Asthma) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 53 Pages
|Pulmicort(氣喘):市場預測與分析 Pulmicort (Asthma) - Forecast and Market Analysis to 2023|
|出版日期: 2014年08月31日||內容資訊: 英文 53 Pages||
Pulmicort是由AstraZeneca在1997年所開發的ICS(吸入用類固醇藥)治療方法，用於預防及幼兒期·成人期的氣喘維持治療上。活性物質Budesonide是具有抗發炎效果的皮質類固醇，與其受體具有高度親和性。AstraZeneca銷售的Pulmicort衍生產品有Flexhaler(成人及6歲以上患者用)和Pulmicort Respules(1∼8歲的幼兒用)、Pulmicort Turbuhaler(支氣管氣喘患者用)等。
GlobalData has released its new PharmaPoint Drug Evaluation report, "Pulmicort (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
AstraZeneca's Pulmicort is an ICS therapy that was originally launched in 1997, and is used prophylactically for the maintenance treatment of asthma in children and adults. Its active ingredient, budesonide, is an anti-inflammatory corticosteroid with a high affinity for the corticosteroid receptor. AstraZeneca's Pulmicort franchise includes the Pulmicort Flexhaler (budesonide) for adults and pediatric patients older than six years of age, Pulmicort Respules for children between one and eight years of age, and the Pulmicort Turbuhaler for patients with bronchial asthma.